Profhilo Singapore Bio-Remodelling, Explained

What Profhilo actually is

Profhilo is an injectable preparation of hyaluronic acid, but it belongs to a different category from the hyaluronic acid fillers most people have heard of. It contains two populations of hyaluronic acid — one of high molecular weight, one of low — combined into what the manufacturer calls a hybrid cooperative complex, under the trade name NAHYCO. A 2 mL syringe carries 32 mg of each.

The distinction that matters clinically is the absence of a chemical crosslinker. Conventional hyaluronic acid fillers are crosslinked, usually with BDDE, so that the gel resists degradation and holds a shape under the skin. That is what allows a filler to project a chin or support a cheek. Profhilo is stabilised by a thermal process instead, and holds no shape at all. Injected, it spreads.

So the two products answer different questions. A filler answers where is volume missing. Profhilo answers how is this skin behaving.

Why it is not a filler, and why that matters

This is the single most common misunderstanding, and it is worth being blunt about, because it is the reason people come away unimpressed.

If the complaint is a flat midface, a receded chin or a deep nasolabial fold driven by volume loss, Profhilo will not address it. Those are structural problems and they need something that holds structure — a crosslinked filler, or in some cases a different approach entirely. Profhilo placed into that situation will not produce the change the patient came for, and no amount of it will.

Where it is the right tool is the opposite situation: skin that has lost quality rather than volume. Crepiness. A dull, thin, poorly hydrated surface. Fine lines that sit on the skin rather than in the underlying shape. Necks and the backs of hands, where there is little to volumise and a great deal of surface change.

A sensible consultation separates those two things before anything is injected. Volume restoration and bio-remodelling are not competing options; they answer different complaints, and a face often needs the first before the second is worth doing.

The BAP injection pattern, and why those points

Profhilo is not injected across the face the way a mesotherapy cocktail is. It is placed at a defined set of points per side — the Bio Aesthetic Points, or BAP — and those positions were not chosen for convenience.

They were chosen for two reasons. The first is vascular safety: each point sits away from the major facial vessels, which matters for any injectable placed in the subcutaneous plane. The second is spread. Because the product is uncrosslinked and low in viscosity, it diffuses through the subcutaneous layer from the point of deposit, so a small number of correctly placed boluses can cover a region that would otherwise need many superficial punctures.

That property is also why the injection is given with a fine needle despite the relatively high hyaluronic acid concentration — the hybrid complex has markedly lower dynamic viscosity than high-molecular-weight hyaluronic acid alone.

A modified BAP — how Dr Sin Yong places it

The manufacturer's protocol specifies a fixed set of Bio Aesthetic Points per side. As a default it is sound: the positions are chosen for vascular safety and for predictable spread, and they are the right starting point for anyone working without a detailed assessment of the face in front of them.

Dr Sin Yong treats that set as the safety framework rather than the whole plan. A fixed pattern treats every face as the same face, and faces are not the same. Where the midface has deflated, where the jawline has softened, where the asymmetry sits — those regions place the greatest mechanical demand on the skin, and they do not always coincide with the standard points.

So the technique he uses keeps the defined points and adds placement according to the shape of the individual face. The anatomical rules governing where an injectable may safely sit do not change. What changes is the map.

He also places it into scarred skin, which the standard protocol does not address. Scar tissue is organised differently from the skin around it and behaves differently, and treating it alongside the rest of the face is a deliberate part of the plan rather than an afterthought.

This is the part that does not transfer from a brochure. It is also why the same product, in different hands, is not the same treatment.

What the published evidence actually shows

The laboratory work behind the product is reasonably well characterised, and it is worth separating what has been measured from what is claimed in marketing.

The foundational study, published in PLoS ONE in 2016, examined hybrid cooperative complexes against the individual hyaluronic acid weights in skin cell models. Two findings are relevant. First, durability: roughly 35% of the high-molecular-weight material remained after ten days of exposure to hyaluronidase, against under 10% for standard high-molecular-weight hyaluronic acid on its own. Second, cellular response: the complexes increased gene expression of collagen types I, III, IV and VII and of elastin relative to the individual components, with type III collagen expression in fibroblasts rising roughly twelve-fold.

Those are laboratory measurements of gene expression in cell models. They explain the proposed mechanism; they are not a statement of what any individual's skin will do. There is also an open-label study in Asian patients, which is the more relevant population for Singapore, and a body of review literature on hybrid cooperative complexes in aesthetic medicine. All are listed in the references below.

Profhilo Structura is a different product

Profhilo Structura is searched for almost as often as Profhilo itself, and the two are routinely conflated. They are separate products from the same manufacturer.

Standard Profhilo is directed at skin quality through the mechanism described above. Structura is formulated for structural support in the deeper plane, which places it closer to the volumising end of the spectrum than Profhilo is — though it is still not a conventional crosslinked filler. They answer different complaints, and a clinic offering one is not necessarily offering the other.

If you have been quoted for “Profhilo” without being told which, that is worth clarifying before you proceed.

Who it suits, and who it does not

It suits skin where the surface quality has changed but the underlying shape has not: crepey texture, loss of hydration and light reflectance, early fine lines, a neck that has begun to show horizontal lines without significant laxity.

It does not suit a face whose main problem is descent or volume loss. It does not tighten skin in the way an energy-based device does — if the complaint is jowling or a loose jawline, focused ultrasound or radiofrequency is the relevant category, not an injectable hyaluronic acid. See HIFU and the VF Lift – Vertical Facelift for that distinction.

It is also not the right first step in a face that has never been assessed. A good deal of disappointment with injectables comes from treating the layer that is easiest to reach rather than the layer that is causing the complaint.

Risks, limits and what to expect of the procedure

The common findings after injection are those of any intradermal or subcutaneous injectable: small raised deposits at the injection points that settle, bruising, tenderness, and transient swelling. Because the product is placed as discrete boluses, visible blebs at the points immediately afterwards are expected rather than a complication.

The serious risks are the ones that attend any injectable placed near facial vasculature, which is the reason the injection points are specified rather than improvised, and the reason the injector's anatomical knowledge matters more than the product does.

Hyaluronic acid products, including uncrosslinked ones, are degraded by hyaluronidase. The practical consequence is that this is not a permanent intervention and the skin returns to its own trajectory once the material is gone.